Sep 18 |
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
|
Sep 11 |
Owning 39% shares,hedge funds owners seem interested in Immunic, Inc. (NASDAQ:IMUX),
|
Sep 4 |
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
|
Aug 28 |
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
|
Aug 9 |
Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript
|
Aug 8 |
Immunic GAAP EPS of -$0.21 beats by $0.02
|
Aug 8 |
Immunic: Q2 Earnings Snapshot
|
Aug 8 |
Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
Aug 7 |
Immunic Q2 2024 Earnings Preview
|
Aug 1 |
Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
|